Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen to Record $50M-$60M Charge in Q4 Related to Epoch Acquisition

NEW YORK, Feb. 14 (GenomeWeb News) - Nanogen will record a non-cash accounting charge of between $50 million and $60 million for the quarter ended Dec. 31 relating to a change in goodwill accounting as part of its December 2004 acquisition of Epoch Biosciences.


The company said an increase in Nanogen's stock price between the day the acquisition deal was signed and the day it closed was a "significant factor" in the adjustment, according to a statement filed yesterday with the US Securities and Exchange Commission .


Nanogen said the stock-based valuation of the transaction increased by approximately $35 million.


The company expects to announce "within a week" a date for its fourth-quarter earnings release.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.